ArticleAnnals of nuclear medicine2026
Lymphatic mapping and sentinel lymph node biopsy in urinary bladder cancer: A SPECT/CT-based experience.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveSentinel lymph node (SLN) mapping in bladder cancer has the potential to improve nodal staging while minimizing the morbidity associated with pelvic lymph node dissection (PLND). However, its feasibility, diagnostic accuracy, and influencing factors-including tumor stage, neoadjuvant chemotherapy (NAC), and imaging modality-remain under investigation. MATERIALS AND
methodsIn this prospective study, 35 patients with T1-T4 urothelial carcinoma undergoing radical cystectomy and bilateral PLND were enrolled. Preoperative cystoscopic peritumoral injection of
resultsA total of 54 SLNs were identified in 24 patients (37 hemipelves). Patient-based detection rates were 68.6% for intraoperative gamma probe, 51.4% for SPECT/CT, and 45.7% for planar imaging. Hemipelvis-based detection rates were 52.9%, 40.0%, and 34.3%, respectively. Detection rates were highest in T1-T2, NAC-positive patients, with 100% intraoperative localization. Histopathological analysis identified nodal metastases in seven patients; SLNs were identified in four patients, three of whom showed concordant SLN involvement, while one showed no SLN involvement. The patient-based false-negative rate was 25%, while hemipelvis-based analysis showed no false negatives. Aberrant SLNs outside the standard PLND template were identified in 6% of patients, highlighting variable lymphatic drainage.
conclusionSLN mapping in bladder cancer is technically feasible and identifies atypical drainage patterns, with performance influenced by tumor stage, NAC, and imaging modality. SLN mapping may complement PLND by improving anatomical staging and may ultimately allow more tailored or minimally invasive lymphadenectomy in selected patients.
Indexed as
Identifiers
41824256What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.